Northland Securities Predicts Brainsway Q3 Earnings

Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY) – Equities researchers at Northland Securities issued their Q3 2026 earnings per share (EPS) estimates for Brainsway in a note issued to investors on Thursday, January 22nd. Northland Securities analyst C. Byrnes forecasts that the company will post earnings of $0.14 per share for the quarter. The consensus estimate for Brainsway’s current full-year earnings is $0.08 per share. Northland Securities also issued estimates for Brainsway’s Q4 2026 earnings at $0.16 EPS.

Brainsway (NASDAQ:BWAY) last posted its quarterly earnings data on Tuesday, November 11th. The company reported $0.08 earnings per share for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.03). The company had revenue of $13.51 million for the quarter, compared to analysts’ expectations of $13.04 million. Brainsway had a net margin of 12.73% and a return on equity of 9.46%.

Several other research analysts also recently weighed in on the stock. Wall Street Zen downgraded shares of Brainsway from a “buy” rating to a “hold” rating in a report on Friday. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Brainsway in a research note on Monday, December 29th. Finally, HC Wainwright increased their target price on Brainsway from $18.00 to $24.00 and gave the stock a “buy” rating in a research report on Monday, December 8th. Two investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $27.00.

Brainsway Price Performance

BWAY opened at $23.04 on Monday. The company has a 50 day simple moving average of $18.88 and a two-hundred day simple moving average of $16.13. The firm has a market cap of $451.12 million, a P/E ratio of 76.80 and a beta of 1.19. Brainsway has a 1-year low of $7.84 and a 1-year high of $24.84.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. ARK Investment Management LLC increased its stake in Brainsway by 6.1% during the second quarter. ARK Investment Management LLC now owns 199,826 shares of the company’s stock worth $2,628,000 after acquiring an additional 11,498 shares during the last quarter. Huntleigh Advisors Inc. lifted its stake in shares of Brainsway by 5.7% in the 2nd quarter. Huntleigh Advisors Inc. now owns 77,416 shares of the company’s stock valued at $1,018,000 after purchasing an additional 4,143 shares during the last quarter. NewEdge Advisors LLC boosted its holdings in shares of Brainsway by 61.5% in the 1st quarter. NewEdge Advisors LLC now owns 19,828 shares of the company’s stock worth $188,000 after purchasing an additional 7,549 shares during the period. Raymond James Financial Inc. bought a new position in shares of Brainsway during the 2nd quarter valued at approximately $85,000. Finally, UBS Group AG increased its position in shares of Brainsway by 2,028.6% during the 3rd quarter. UBS Group AG now owns 63,878 shares of the company’s stock valued at $963,000 after purchasing an additional 60,877 shares during the last quarter. Institutional investors own 30.11% of the company’s stock.

Brainsway Company Profile

Brainsway Ltd is a medical device company specializing in non-invasive neuromodulation therapies. Publicly traded on the NASDAQ under the symbol BWAY, the company develops and commercializes deep transcranial magnetic stimulation (Deep TMS) systems designed to treat a range of neuropsychiatric and neurological disorders. Brainsway’s technology aims to offer an alternative or complement to traditional pharmacological therapies by targeting precise brain regions with its patented coil designs.

The company’s flagship Deep TMS platform utilizes proprietary H-coil arrays engineered to reach deeper cortical structures than conventional TMS devices.